News

ReAlta Life Sciences Expands Phase 1 Clinical Trial of RLS-0071

ReAlta Life Sciences (“ReAlta”), Inc., a company addressing life-threatening diseases through harnessing the power of the immune system, today announced that it has received a no objection letter (NOL) from Health Canada to an Amendment of the Company’s Phase 1 clinical trial of RLS-0071 in healthy volunteers. The study design has been modified to add three multiple ascending dose (MAD) cohorts and an additional single ascending high dose (SAD) cohort to the trial.

“The revised trial design amendment will enable us to expeditiously execute the SAD and MAD parts of this Phase 1 clinical trial and obtain important PK-PD, safety and tolerability data that will inform future Phase 2 clinical trial protocols addressing our target indications,” said Ulrich Thienel, M.D., Ph.D., ReAlta’s Chief Executive Officer. “We look forward to providing additional updates on the trial and obtaining data from this study as it progresses and continues to support our other programs.”

Prior to the amendment, the Phase 1 trial was a single ascending dose randomized, double-blind, placebo-controlled, adaptive-design study to evaluate the safety, tolerability, PK and PD of RLS-0071 in healthy subjects.

Recent News

12/05/2022

Danville organization invests in Blacksburg’s CytoRecovery medical cell sorting company

Danville’s investment might mean a CytoRecovery presence in Danville, such as office operations or an internship at Danville Community College. CytoRecovery’s cell sorting could improve understanding of disease and development of drugs. CytoRecovery, an early-stage company that invented and patented less invasive cell sorting, will be able to bring its cell research platform to market

12/01/2022

Ceres Nanosciences Receives $1.4M From NIH RADx Initiative to Add Five Additional Wastewater-Based Epidemiology Centers of Excellence

MANASSAS, Virginia – Ceres Nanosciences (Ceres), a privately held company that makes innovative products to improve life science research and diagnostic testing, is announcing today that it is expanding the network of wastewater-based epidemiology centers of excellence that was established with support from the National Institutes of Health (NIH) RADx® initiative. With a new $1.4

11/16/2022

Alliance for Building Better Medicine Names Joy Polefrone as Executive Director

Joy Polefrone, Ph.D. will Lead the Organization in Its Mission to Create a Reliable Supply of Safe, High-Quality, and Affordable Medicines in the U.S. Richmond/Petersburg– Alliance for Building Better Medicine, a coalition of public and private sector stakeholders in the Richmond-Petersburg region, today announced that it has appointed Joy Marie Polefrone, Ph.D., as the organization’s executive director.